John C.K. Iv Milligan Sells 258,000 Shares of TherapeuticsMD Inc (TXMD) Stock

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan sold 258,000 shares of TherapeuticsMD stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $4.77, for a total transaction of $1,230,660.00. Following the sale, the insider now directly owns 1,601,419 shares in the company, valued at $7,638,768.63. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

John C.K. Iv Milligan also recently made the following trade(s):

  • On Tuesday, December 4th, John C.K. Iv Milligan sold 129,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.98, for a total transaction of $642,420.00.
  • On Thursday, November 29th, John C.K. Iv Milligan sold 258,128 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.96, for a total transaction of $1,280,314.88.
  • On Thursday, November 15th, John C.K. Iv Milligan sold 258,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.90, for a total transaction of $1,264,200.00.
  • On Wednesday, October 24th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.35, for a total transaction of $1,337,500.00.
  • On Wednesday, October 10th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.85, for a total transaction of $1,462,500.00.
  • On Wednesday, September 26th, John C.K. Iv Milligan sold 125,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.78, for a total transaction of $847,500.00.
  • On Tuesday, September 11th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.10, for a total transaction of $1,525,000.00.

NASDAQ:TXMD opened at $4.53 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 7.15 and a current ratio of 7.23. TherapeuticsMD Inc has a one year low of $4.30 and a one year high of $7.66. The company has a market cap of $1.15 billion, a P/E ratio of -12.24 and a beta of 1.35.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Wednesday, November 7th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The business had revenue of $3.47 million for the quarter, compared to the consensus estimate of $4.43 million. During the same period last year, the company earned ($0.07) EPS. The firm’s revenue was down 21.5% compared to the same quarter last year. On average, analysts expect that TherapeuticsMD Inc will post -0.58 earnings per share for the current fiscal year.

TXMD has been the topic of several research reports. Cantor Fitzgerald set a $26.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Friday, August 10th. BidaskClub upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, November 23rd. Zacks Investment Research downgraded shares of TherapeuticsMD from a “buy” rating to a “sell” rating in a research report on Wednesday, October 24th. Oppenheimer set a $14.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, ValuEngine downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average target price of $13.45.

A number of large investors have recently bought and sold shares of TXMD. Vanguard Group Inc. lifted its position in shares of TherapeuticsMD by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 12,894,027 shares of the company’s stock worth $84,585,000 after purchasing an additional 1,153,716 shares during the period. B. Riley Wealth Management Inc. acquired a new position in shares of TherapeuticsMD in the 3rd quarter worth approximately $102,000. Teachers Advisors LLC lifted its position in shares of TherapeuticsMD by 13.3% in the 3rd quarter. Teachers Advisors LLC now owns 353,895 shares of the company’s stock worth $2,322,000 after purchasing an additional 41,607 shares during the period. MetLife Investment Advisors LLC lifted its position in shares of TherapeuticsMD by 54.0% in the 3rd quarter. MetLife Investment Advisors LLC now owns 121,657 shares of the company’s stock worth $798,000 after purchasing an additional 42,669 shares during the period. Finally, Nexthera Capital LP acquired a new position in shares of TherapeuticsMD in the 3rd quarter worth approximately $8,575,000. Institutional investors and hedge funds own 72.66% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/12/08/john-c-k-iv-milligan-sells-258000-shares-of-therapeuticsmd-inc-txmd-stock.html.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Further Reading: Why does a company issue an IPO?

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply